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Many cancers express Fas ligand (FasL/CD95L) in vivo, and can kill lymphoid cells by Fas-mediated apoptosis in vitro. However,
overexpression of recombinant FasL in murine tumour allografts revealed a potential antitumour effect of FasL, via recruitment of
neutrophils. Transforming growth factor-b1 (TGF-b1) could inhibit these neutrophil-stimulatory effects of FasL. In the present study,
we sought to determine directly whether FasL contributes to immune privilege or tumour rejection in human colon cancers in vivo,
and whether TGF-b1 regulates FasL function. Serial tumour sections were immunostained for FasL and TGF-b1. Neutrophils and
tumour infiltrating lymphocytes (TILs) were detected by immunohistochemistry for lactoferrin and CD45, respectively. Apoptotic TIL
were identified by dual staining for TUNEL/CD45. FasL expression by nests of tumour cells was associated with a mean four-fold
depletion of TILs (range 1.8–33-fold, n¼16, Po0.001), together with a two-fold increase in TIL apoptosis (range 1.6–2.5-fold,
n¼14, Po0.001), relative to FasL-negative nests within the same tumours. The overall level of neutrophils present in all tumours
examined was low (mean 0.3%, n¼16), with FasL expression by tumour nests associated with a mean two-fold decrease in
neutrophils, irrespective of TGF-b1 expression. Together, our results suggest that tumour-expressed FasL is inhibitory rather than
stimulatory towards antitumour immune responses.
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Colorectal cancer represents a formidable health care problem,
being one of the major causes of cancer death (Greenlee et al,
2001). Despite infiltration of colonic carcinoma tissue with
lymphocytes, the immune system fails to effectively eliminate
these malignant cells. A number of immune escape mechanisms
have been identified, ranging from defective antigen processing
and presentation (Kaklamanis et al, 1995; Johnsen et al, 1999) to
the production of immunosuppressive factors (O’Mahony et al,
1993; Luo et al, 1997). Recent studies have identified an additional
mechanism of tumour immune evasion involving expression of the
apoptosis-inducing protein Fas ligand (FasL/CD95L) (O’Connell
et al, 1996). FasL is a member of the TNF family, which can trigger
apoptotic cell death following ligation to its receptor, Fas (CD95/
APO-1) (Nagata and Golstein, 1995). This interaction plays an
important role in immune homeostasis (Nagata, 1999) and in the
maintenance of immune privilege in certain organs such as the eye
(Griffith et al, 1995). The discovery of FasL expression by a variety
of tumour cells (Bennett et al, 1998; O’Connell et al, 1998; Mann
et al, 1999) raised the possibility that FasL may also mediate
immune privilege in human tumours. Tumour infiltrating
lymphocytes (TILs) express Fas (Cardi et al, 1998) and are
sensitive to Fas-mediated apoptosis. In contrast, many human
tumours have been shown to be resistant to FasL-induced cell
death (O’Connell et al, 2000). Thus, upregulation of FasL
expression would allow tumour cells to kill infiltrating antitumour
lymphocytes. Several studies have shown that tumour-expressed
FasL is capable of killing Fas-bearing, sensitive cells in vitro
(O’Connell et al, 1996; Yoong et al, 1999), while expression of FasL
by human tumours in vivo is associated with apoptosis and loss of
TILs (Bennett et al, 1998). Thus, FasL expression by human
tumours may enable the tumour cells to counterattack antitumour
effector cells with one of their own apoptosis triggers: FasL.
Based on the ability of FasL to eliminate activated, Fas
þ T cells,
it was hoped that forced expression of FasL would protect
allografts from lymphocyte-mediated effector mechanisms. How-
ever, rodent transplantation experiments involving FasL have
yielded conflicting results. Several groups demonstrated enhanced
allograft survival following direct transfection of FasL cDNA into
allografts (Li et al, 1998; Tourneur et al, 2001). Cotransplantation
of FasL-negative allografts with FasL-expressing cells was also
reported to prevent allograft rejection (Korbutt et al, 1997; Takeda
et al, 1998). This contrasts with other studies where genetically
engineered overexpression of FasL resulted in inflammation and
allograft rejection (Allison et al, 1997; Seino et al, 1997a). Rejection
was characterised by massive neutrophil infiltration and acceler-
ated allograft destruction. Cotransfection of the immunosuppres-
sive cytokine transforming growth factor-b1 (TGF-b1) with FasL
was sufficient to inhibit the neutrophil-stimulatory activity of FasL,
resulting in allograft survival (Chen et al, 1998). These findings
raise the question as to whether endogenous expression of FasL by
human tumours, instead of mediating immune privilege, is in fact
detrimental to the survival of the tumour due to neutrophil Received 21 March 2003; revised 2 July 2003; accepted 3 July 2003
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srecruitment. In particular, does TGF-b1 determine FasL activity in
vivo, such that FasL mediates tumour immune privilege where
TGF-b1 is coexpressed, but recruits neutrophils in its absence?
In the present study, we sought to determine directly if FasL
expression by nests of colon tumour cells was associated with
increased apoptosis of TILs, thereby contributing to the immune
privilege of the tumour. We ascertained the level of neutrophil
infiltration in the same colon tumours, and determined whether
there was any local recruitment of neutrophils into FasL-
expressing tumour nests. We also determined whether the level
of neutrophil infiltration into FasL-positive tumour nests was
affected by the presence or absence of tumour-expressed TGF-b1.
METHODS
Tissues
Human colonic adenocarcinomas (n¼16) were collected following
surgical resection at the Mercy Hospital, Cork, following a protocol
approved by the University Teaching Hospitals Ethics Committee.
None of the patients had received chemo-, radio- or immunother-
apy prior to tissue collection. Specimens included tumours of all
Dukes’ stages: A (n¼2), B (n¼7), C (n¼4) and D (n¼3).
Immunohistochemical detection of FasL and TGF-b
protein
Formalin-fixed, paraffin-embedded colonic tumour sections were
deparaffinised in xylene and rehydrated prior to analysis. Antigen
retrieval was performed by microwave irradiation in 0.01 M citrate
buffer, pH 6.0. Slides were washed with TBS containing 0.001%
saponin, and endogenous peroxidase was quenched with 3.0%
hydrogen peroxide in methanol for 5min. Nonspecific binding was
blocked with 5% NGS in wash buffer for 1h. To detect FasL
expression, adjacent sections were incubated overnight at 41C with
two different anti-FasL antibodies   rabbit polyclonal anti-human
FasL-specific IgG (C-20; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 0.2mgml
 1 and FasL-specific monoclonal antibody
(clone G247-4; PharMingen, San Diego, CA, USA) at 5mgml
 1.
Antibody binding was localised using a biotinylated secondary
antibody, avidin-conjugated HRP and DAB substrate, contained
within the Vectastain ABC detection kit (Vector Laboratories,
Burlingame, CA, USA). Slides were counterstained with haematox-
ylin. The immunising peptide was included at 2mgml
 1 during
primary antibody incubation in control staining for the Santa Cruz
antibody, while an isotype-matched control in place of the primary
antibody was used for the monoclonal antibody.
Transforming growth factor-b1 expression was detected in a
similar fashion except that antigen retrieval involved treating the
slides with hyaluronidase (1mgml
 1) for 30min at room
temperature. TGF-b1 protein was detected using a polyclonal
anti-human TGF-b1-specific IgG (R&D Systems, UK) at 1mgml
 1.
Immunohistochemical detection of leucocytes (CD45) and
neutrophils (lactoferrin)
Tumour-infiltrating immunocytes and neutrophils were identified
by immunostaining for CD45 (leucocyte common antigen) and
lactoferrin, respectively. Following deparaffinisation and rehydra-
tion, antigen retrieval was performed by microwave irradiation in
0.01 M citrate buffer, pH 6.0. The slides were incubated with mouse
anti-human CD45 monoclonal IgG (Dako Corp., Carpinteria, CA,
USA) diluted 1:70, or mouse anti-human lactoferrin monoclonal
IgG (PharMingen) at 10mgml
 1 for 1h. Antibody binding was
detected using a secondary rabbit anti-mouse IgG (Dako Corp.) at
a dilution of 1:25, followed by alkaline phosphatase-conjugated
anti-alkaline phosphatase (APAAP) complex (Dako Corp.) at a
dilution of 1:50. Sections were then incubated for 10min, with an
alkaline phosphatase substrate solution (Fast Red; Sigma Chemical
Co., St. Louis, MO, USA). Positive cells appeared red when viewed
under light microscopy.
Detection of apoptotic TILs by CD45/TUNEL dual staining
CD45/TUNEL dual staining was performed to allow apoptotic TILs
to be identified and enumerated within the colonic tumours. CD45
staining was performed first on colonic tumour sections as
described, except that the colour substrate used was Fast Blue
(Sigma Chemical Co.). Cell death was then detected in situ by
enzymatic labelling of DNA strand breaks using terminal
deoxynucleotidyl transferase-mediated dUTP nick end labelling
(TUNEL) (Roche Molecular Biochemicals, Indianapolis, IN, USA),
according to the manufacturer’s instructions. When viewed under
light microscopy, nonapoptotic CD45-single-positive cells stained
blue, while apoptotic CD45/TUNEL dual-positive cells exhibited
brown nuclear staining with blue cytoplasmic/cell surface staining.
Cell counting and labelling indices
To quantify CD45-positive TIL infiltration of FasL-positive vs
FasL-negative tumour nests, stained tumour sections were
analysed under light microscopy as previously described (Bennett
et al, 1998). Briefly, FasL-positive and FasL-negative areas were
located on a FasL-stained colonic tumour section by one
investigator. A consecutive, CD45-stained slide from the same
tumour was superimposed on the FasL-stained slide. Using
histological landmarks, the corresponding FasL-positive and
FasL-negative areas were located on this slide. The FasL-stained
section was removed, and a second investigator, blinded as to the
local status of FasL expression, counted the number of CD45-
positive TIL per 2000 total nuclei in the area located by the first
investigator. A similar approach was employed to enumerate
CD45/TUNEL dual-positive TIL, and lactoferrin-positive neutro-
phils within FasL-positive vs FasL-negative areas of colonic
tumours. For each type of staining, slides from all tumour
specimens were stained in a single experiment.
Labelling indices for TIL infiltration and neutrophil recruitment
were expressed as the percentage CD45-positive or the percentage
lactoferrin-positive cells per 2000 total nuclei counted. Labelling
indices for TIL apoptosis were expressed as the percentage CD45/
TUNEL dual-positive cells per 500 total CD45-positive cells
counted.
RESULTS
Local expression of FasL by nests of colon tumour cells is
associated with reduced TIL infiltration
Using a FasL-specific rabbit polyclonal antibody, FasL was found
to be expressed on tumour cells from 16 surgically resected colon
cancers, as revealed by intense immunohistochemical staining.
Staining within individual tumours varied in intensity and extent,
with FasL-positive and FasL-negative neoplastic regions coexisting
within all tumours. FasL expression by some TILs was also
detected in all specimens. Since questions have been raised
regarding the specificity of some anti-FasL antibodies (Stokes et al,
1998), FasL expression was confirmed by immunohistochemistry
on consecutive tumour sections using two different FasL-specific
antibodies (clone G247-4, PharMingen; clone C20, Santa Cruz
Biotechnology). There was good agreement between the results
obtained with the two antibodies; the pattern of FasL detection
corresponded exactly between the consecutive sections (Figure 1).
Leucocyte infiltration in tumours was assessed by immunohis-
tochemical staining for the leucocyte common antigen (CD45).
Although all tumours exhibited infiltration by lymphocytes, within
individual tumours there was marked regional variation in the
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snumbers of infiltrating lymphocytes. To evaluate whether FasL
expression by colon tumour cells affected the level of TILs, the
number of CD45-positive TILs within FasL-positive vs FasL-
negative tumour cell nests was assessed. Using a reference section
immunohistochemically stained for FasL to identify FasL-positive
and FasL-negative tumour nests, we found that there were
consistently fewer TILs within FasL-expressing nests relative to
FasL-negative tumour nests within each tumour examined (n¼16)
(Figure 2). Results revealed that there was a mean four-fold fewer
TILs in tumour nests that expressed FasL relative to those nests
that did not express FasL (range 1.8–33-fold, n¼16, Po0.001;
Wilcoxon signed rank) (Figure 3A). This indicated that FasL
expression by nests of colon tumour cells appeared to have an
inhibitory effect on infiltration by TILs.
FasL expression in colon tumour nests is associated with
increased apoptosis of TILs
To investigate if the impaired lymphocyte infiltration into FasL-
expressing colon tumour nests was due to apoptotic depletion, we
performed dual staining combining TUNEL with immunohisto-
chemistry for CD45. Using reference sections immunohistochemi-
cally stained for FasL, intratumoral variation in the level of TIL
apoptosis was observed, with consistently more apoptosis of TILs
in FasL-expressing tumour nests (Figure 2). Significantly, there
were consistently two-fold more apoptotic TILs within tumour
nests that expressed FasL relative to those nests that did not
(Figure 3B) (range 1.6–2.5-fold, n¼14, Po0.001; Wilcoxon signed
rank) (n¼14; two of the 16 tumours did not contain sufficient
FasL-negative nests to reach a count of 500 TILs). Together, these
results demonstrate that FasL expression by colon tumour nests is
associated with apoptosis of CD45-positive TILs, resulting in
depletion of TILs within these tumour nests.
FasL expression in colon cancer is not associated with
recruitment of neutrophils
Given the recent findings that transplantation of allografts
genetically engineered to express FasL may result in neutrophil
recruitment and graft rejection, we sought to determine if
endogenous FasL expressed by colon tumour nests was proin-
flammatory and responsible for any local recruitment of neutro-
phils. The extent of neutrophil recruitment was determined by
counting the number of neutrophils within adjacent FasL-positive
and FasL-negative tumour nests. Neutrophils were identified based
on their characteristic multi-lobed nuclei, together with immuno-
histochemical staining for the neutrophil marker lactoferrin
(Figure 2). The overall level of neutrophils present within the
Figure 1 Human colon adenocarcinomas express FasL. FasL expression
on consecutive tumour sections was determined by immunoperoxidase
staining, using two different antibodies – (A) rabbit polyclonal (C-20; Santa
Cruz Biotechnology) and (B) monoclonal (clone G247-4; PharMingen)
FasL-specific antibody. FasL-expressing (brown) tumour nests (black
arrows) could be identified adjacent to FasL-negative tumour nests (white
arrows) within each colonic adenocarcinoma. There was a good agreement
between the immunohistochemical staining pattern obtained with both
antibodies, confirming the specificity of FasL detection. Original magnifica-
tion:  200.
Figure 2 Increased apoptosis leading to depletion of TILs in FasL-
expressing nests of colonic adenocarcinomas. A–F, FasL-specific immu-
nohistochemical staining (brown) allowed identification of (A) FasL-
expressing and (B) FasL-negative tumour nests in close proximity within
individual colonic adenocarcinomas. On a consecutive tumour section, TILs
were identified by immunohistochemical staining for CD45 (red).
Significantly fewer TILs were evident in tumour nests that expressed FasL
(C) relative to nests that were negative for FasL (D). Tumour-infiltrating
lymphocytes that were undergoing apoptosis were identified by CD45–
TUNEL dual staining on another consecutive section (E and F). Apoptotic
TIL exhibited brown TUNEL-positive nuclear staining with blue CD45-
positive cytoplasmic/cell surface staining (black arrows, E). Apoptosis was
significantly less frequent among TILs within FasL-negative tumour nests
(F), where a high proportion of TILs showed absence of TUNEL staining
(white arrows), against a blue CD45-positive cytoplasmic background (inset
F). FasL expressed in human colon cancer does not recruit neutrophils.
G,H, Neutrophils were identified by immunohistochemical staining for
lactoferrin (red), together with their multi-lobed nucleus (inset H). There
was no significant difference in the level of neutrophil infiltration between
colon tumour nests that expressed FasL (G) and tumour nests that were
negative for FasL (H). Original magnifications:  400 (A–H) and  1000
(insets, E, F and H). The results shown are representative of 16 colonic
adenocarcinomas.
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stumour specimens was low (mean¼0.3%, n¼16) (Table 1) In
particular, there was a lack of neutrophil recruitment in response
to tumour-expressed FasL. There were two-fold fewer neutrophils
in tumour nests that expressed FasL compared to nests that did not
express FasL (n¼16) (Figure 3C). Activated neutrophils have
previously been shown to be sensitive to Fas-mediated apoptosis in
vitro (Liles et al, 1996). Our findings are consistent with a role for
colon tumour-expressed FasL in causing apoptosis rather than
activation or recruitment of neutrophils.
Lack of FasL-mediated recruitment of neutrophils in colon
cancer is not dependent on expression of TGF-b1
Since TGF-b1 has been shown to be capable of controlling the
proinflammatory effects of FasL overexpression (Chen et al, 1998),
we sought to determine if expression of TGF-b1 might account for
the lack of neutrophil recruitment in FasL-positive colon cancers.
Immunohistochemical staining identified TGF-b1-producing neo-
plastic cells within our panel of colon adenocarcinomas. The
expression of TGF-b1 was variable in the tumours (n¼16): four
were strongly positive, five were moderate or weakly positive, and
seven were negative (Table 1). The seven tumours that were
completely negative for TGF-b1 were strongly positive for FasL, yet
the overall level of neutrophil infiltration in these tumours was
low, and was not higher than in tumours that coexpressed FasL
and TGF-b1. Examination of individual tumour sections revealed
that there was no local recruitment of neutrophils into tumour
nests that were positive for FasL and negative for TGF-b1, or into
nests that coexpressed FasL and TGF-b1 (Figure 4). Hence,
tumour-expressed FasL is not associated with general or local
neutrophil recruitment in the tumour microenvironment. This is
irrespective of whether TGF-b1 is coexpressed or not. Moreover,
the increased apoptosis of TILs found in FasL-expressing tumour
nests was not dependent on TGF-b1 expression. The overall
apoptotic rates of TILs in TGF-b1-expressing tumours
(mean¼33.81%) and TGF-b1-negative tumours (mean¼35.67%)
were not significantly different (P¼0.282; Mann–Whitney U test)
(Figure 5).
DISCUSSION
Despite compelling evidence demonstrating an immune evasive
function for tumour-expressed FasL, controversy surrounds this
protein (O’Connell et al, 2001; Restifo, 2000), with some reports
suggesting that FasL expression by tumour cells is proinflamma-
tory and accelerates tumour elimination. Thus, in the present
study, the ability of colon tumour-expressed FasL to eliminate TILs
and to contribute to local immune suppression was analysed
directly in situ. The expression of FasL by human colon cancer
cells is well established. Using multiple techniques, including in
situ hybridisation for FasL mRNA and immunodetection for FasL
protein using a variety of different FasL-specific antibodies, FasL
expression by colon cancer has been demonstrated both in vivo
and in vitro (Shiraki et al, 1997; O’Connell et al, 1998; Mann et al,
1999; Yoong et al, 1999). Furthermore, several studies have
demonstrated the ability of colon tumour cells to kill Fas-sensitive
target cells in vitro. FasL-expressing colon cancer cells have been
shown to kill both co-cultured Fas-sensitive Jurkat T cells
(O’Connell et al, 1996; Shiraki et al, 1997) and primary hepatocytes
(Yoong et al, 1999). FasL-specific antisense oligonucleotide
treatment of the SW620 cells, which transiently inhibited their
ability to express FasL, protected the Jurkat cells from FasL-
mediated killing (O’Connell et al, 1996). We confirmed FasL
expression by human colon adenocarcinomas by immunohisto-
chemistry using two different FasL-specific antibodies. The
examination of consecutively stained sections revealed an identical
immunohistochemical staining pattern with both antibodies,
confirming the specificity of FasL detection.
The expression of FasL by the tumour cells was found to vary
greatly within individual tumours. Since both FasL-positive and
FasL-negative regions coexisted within individual tumours, a direct
analysis of the ability of tumour-expressed FasL to induce
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Figure 3 Local expression of FasL by colon tumour nests causes the
apoptotic depletion of TILs. (A–B), TILs were quantified as percentage
CD45-positive cells per 2000 total nuclei counted. There were four-fold
fewer TILs detectable within tumour nests that expressed FasL (open bar)
compared with nests that did not express FasL (solid bar) (range 1.8–33-
fold, n¼16, Po0.001; Wilcoxon signed rank) (A). TILs undergoing
apoptosis were quantified as percentage TUNEL-CD45 dual positive cells
per 500 total CD45-positive cells detected. There was consistently two-
fold more apoptosis of TILs within tumour nests that expressed FasL (open
bar) compared with nests that did not express FasL (solid bar) in each
tumour (range 1.6–2.5-fold, n¼14, Po0.001; Wilcoxon signed rank) (B).
Local expression of FasL by tumour nests does not recruit neutrophils into
colon cancers. (C), Intratumoral neutrophils were quantified as percentage
lactoferrin-positive cells per 2000 total nuclei counted. The overall level of
neutrophils was low (mean¼0.3%, n¼16). There was no recruitment of
neutrophils into tumour nests that expressed FasL. In contrast, there were
more than twofold fewer neutrophils present in tumour nests that
expressed FasL (open bar) relative to nests that did not (solid bar) (C),
although this difference in neutrophil infiltration was not statistically
significant.
Table 1 Lack of neutrophil recruitment in response to colon tumour-

















1 +++ ++ 0.55 0.85
2 +++ ++ 0.15 1.0
3 +++   0.5 0.05
4 ++++ ++++ 0.25 0.0
5 ++ +++ 0.7 1.95
6 ++++ + 0.0 0.05
7 ++++   0.0 0.0
8 +++ ++++ 0.2 0.35
9 +++   0.0 0.0
10 +++   0.05 0.0
11 ++++ + 0.05 0.3
12 ++++ + 0.2 0.85
13 +++   0.2 0.0
14 ++++   0.15 0.5
15 ++++ +++ 0.0 0.15
16 ++   0.1 0.0
wBased on % positive cells: +¼1 25%; ++¼26 50%; +++¼51 75%;
++++¼76 100%.
z % neutrophil recruitment was calculated as the % lactoferrin-positive cells per 2000
total nuclei counted within FasL-positive/FasL-negative tumour regions.
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spresent study, FasL expression by nests of colon tumour cells was
found to be significantly and consistently associated with increased
apoptosis of TILs, leading to dramatically diminished infiltration of
TILs into these areas of the tumours. There was a consistent (mean
four-fold) decrease in TILs in FasL
þ relative to FasL
  tumour
islands, concomitant with a consistent (mean two-fold) increase in
TIL apoptosis. Since these results are from matched FasL-positive
and FasL-negative tumour islands within the same individual
tumour specimens, the apoptosis and depletion of tumour
infiltrating lymphocytes is unlikely to be due to factors other than
tumour-expressed FasL. Tumour infiltrating lymphocytes express
Fas (Cardi et al, 1998) and activated T cells are sensitive to Fas-
mediated apoptosis (Krammer, 1999). Thus, these results support a
role for FasL in mediating immune privilege in human colon
tumours, via the apoptotic depletion of infiltrating antitumour
lymphocytes. The ability of colon tumour cells to counterattack the
antitumour immune response may provide malignant cells with a
potent mechanism with which to evade the immune system,
promoting the survival and progression of the tumour.
FasL has recently been shown in rodent transplantation studies
to possess proinflammatory activity (Allison et al, 1997; Seino et al,
1997a), suggesting that expression of this protein, instead of
protecting tumour cells from the immune response, could in fact
be detrimental to tumour survival. Inflammation was characterised
by neutrophil recruitment and allograft destruction. Examination
of our tumour specimens revealed that FasL expression by colon
tumour cells is not proinflammatory. Analysis of matched FasL-
positive and FasL-negative tumour nests revealed that local
expression of FasL by tumour cells is not associated with
neutrophil recruitment. Not only was there a lack of neutrophil
infiltration, but in fact there were two-fold fewer neutrophils in
tumour nests that expressed FasL relative to those that did not.
Neutrophils express Fas and are sensitive to Fas-mediated
apoptosis in vitro (Liles et al, 1996), and so perhaps are susceptible
to killing by tumour-expressed FasL in vivo, further impairing the
immune response. Moreover, all studies demonstrating inflamma-
tion and neutrophil recruitment involve forced overexpression of
FasL (Allison et al, 1997; Kang et al, 1997; Seino et al, 1997b).
There are no studies demonstrating FasL-dependent neutrophil
recruitment in response to native FasL. In contrast, under
physiological conditions, native FasL is consistently associated
with apoptosis of activated lymphocytes and immune privilege
(Bellgrau et al, 1995; Bennett et al, 1998). In agreement with this,
our results clearly demonstrate that upregulation of FasL
expression during human colon carcinogenesis does not trigger
neutrophil recruitment.
Recently, TGF-b has been shown in experimental rodent
allograft studies to suppress the proinflammatory activity of
overexpressed FasL. Transformine growth factor-b1 is an im-
munosuppressive cytokine, which inhibits the proliferation and
activity of T cells and NK cells (Letterio and Roberts, 1998). Using
our panel of human colon tumours, we found that lack of
neutrophil recruitment in response to tumour-expressed FasL was
independent of TGF-b1 production by the tumour cells. Transfor-
mine growth factor-b1 was produced with varying extent by 56%
(nine out of 16) of the tumours. Analysis of individual tumours
revealed a lack of neutrophils in FasL-positive tumour nests that
failed to coexpress TGF-b1. In fact, seven of the tumours did not
produce TGF-b1 but expressed FasL, without the presence of a
neutrophilic infiltrate. Furthermore, the apoptotic depletion of
TILs found in FasL-expressing colon tumour nests relative to FasL-
negative tumour nests was independent of TGF-b1 expression by
the tumour cells. Evidence from studies of TGF-b1
 /  mice
suggests that TGF-b1 plays a role in regulating lymphocyte
homeostasis in the periphery, in part by exerting an inhibitory
effect on lymphocyte apoptosis (Bommireddy et al, 2003).
Examination of our tumour specimens revealed that expression



































Figure 5 Expression of TGF-b1 by colon tumours does not correlate
with the overall rate of TIL apoptosis. Apoptotic TILs were quantified as the
percentage TUNEL–CD45 dual positive cells per 500 total CD45-positive
cells counted. There was no significant difference between the overall
percentage of TILs undergoing apoptosis in tumours that expressed TGF-
b1 (solid bar) relative to tumours that did not express TGF-b1 (open bar)
(n¼14, P¼0.282; Mann-Whitney U test).
Figure 4 FasL expression by colonic tumour cells does not mediate
neutrophil recruitment, irrespective of TGF-b1 expression. (A–F), FasL-
expressing tumour cell nests (brown) were identified by immunohisto-
chemistry (A and B). On a consecutive tumour section, TGF-b1-specific
immunoperoxidase staining (brown) allowed the TGF-b1 status of the
colonic tumour cell nests to be identified. FasL-expressing colon tumour
nests that coexpressed (C) and failed to express (D) TGF-b1 could be
identified. Neutrophils were identified by immunohistochemical staining for
lactoferrin (red, arrows) on an adjacent section. The overall level of
neutrophil infiltration was low, irrespective of FasL expression, or of the
presence (E) or absence (F) of TGF-b1. Original magnifications: X 400
(A–f). The results shown are representative of 16 colonic adenocarcino-
mas.
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sapoptosis rate of TILs. Our findings indicate that upregulation of
FasL expression in tumours appears to promote the survival of the
neoplastic cells via apoptotic depletion of TILs, irrespective of the
presence of the immunosuppressive cytokine TGF-b. Establish-
ment of immune privilege is a multifactorial process. In the eye,
FasL and TGF-b represent only two of at least eight independent
mechanisms that function to preclude any potentially destructive
inflammatory responses (Ferguson and Green, 2001). Similarly, the
immune downregulatory activity of FasL may be favoured by a
combination of immunosuppressive processes in the tumour
microenvironment. Selective pressure during tumour development
would ensure that FasL upregulation would only occur where it
would be advantageous to the tumour.
Together, our results show that FasL contributes to immune
privilege in human colon cancer in vivo via apoptotic depletion of
TILs. Despite strong expression of FasL in each specimen, the
overall level of neutrophils present in all of the tumours was low.
Absence of any FasL-induced inflammation was not dependent on
TGF-b coexpression. Thus, upregulation of FasL expression during
colon carcinogenesis is advantageous rather than detrimental to
tumour survival. In fact upregulation of FasL expression by colonic
tumour cells has been shown to occur early on in the pathogenesis
of this malignant disease (Bennett et al, 2001; Shimoyama et al,
2001), suggesting that expression of FasL may be a fundamentally
important and even necessary event in the transformation process.
Functional T cells are central to an intact antitumour immune
response, and so elimination of TILs by apoptosis in response to
tumour-expressed FasL represents a potent mechanism of tumour
immune evasion.
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